ly 106737 has been researched along with naloxone in 4 studies
| Studies (ly 106737) | Trials (ly 106737) | Recent Studies (post-2010) (ly 106737) | Studies (naloxone) | Trials (naloxone) | Recent Studies (post-2010) (naloxone) |
|---|---|---|---|---|---|
| 8 | 0 | 0 | 20,134 | 1,257 | 3,321 |
| Protein | Taxonomy | ly 106737 (IC50) | naloxone (IC50) |
|---|---|---|---|
| Cytochrome P450 2D6 | Homo sapiens (human) | 2 | |
| Delta-type opioid receptor | Mus musculus (house mouse) | 0.043 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0219 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0019 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0019 | |
| Mu-type opioid receptor | Homo sapiens (human) | 0.0397 | |
| Delta-type opioid receptor | Homo sapiens (human) | 0.1896 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.05 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 0.0795 | |
| Mu-type opioid receptor | Mus musculus (house mouse) | 0.0154 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0089 | |
| Beta-2 adrenergic receptor | Cavia porcellus (domestic guinea pig) | 0.0055 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cantrell, BE; Johnson, BG; Leander, JD; Mendelsohn, LG; Mitch, CH; Reel, JK; Snoddy, J; Zimmerman, DM | 1 |
| Belanger, S; Cassel, JA; DeHaven, RN; Dolle, RE; Le Bourdonnec, B; Stabley, GJ | 1 |
| Belanger, S; DeHaven, RN; Dolle, RE; Goodman, AJ; Graczyk, TM; Herbertz, T; Le Bourdonnec, B; Michaut, M; Yap, GP; Ye, HF | 1 |
| Belanger, S; DeHaven, RN; Dolle, RE; Goodman, AJ; Graczyk, TM; Le Bourdonnec, B; Seida, PR | 1 |
4 other study(ies) available for ly 106737 and naloxone
| Article | Year |
|---|---|
Structure-activity relationships of trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine antagonists for mu- and kappa-opioid receptors.
Topics: Analgesia; Animals; Diuresis; Furans; Male; Mice; Molecular Structure; Morphine; Piperidines; Rats; Receptors, Opioid, kappa; Receptors, Opioid, mu; Stereoisomerism; Structure-Activity Relationship | 1993 |
trans-3,4-dimethyl-4-(3-carboxamidophenyl)piperidines: a novel class of micro-selective opioid antagonists.
Topics: Binding, Competitive; Cloning, Molecular; Diprenorphine; Humans; Kinetics; Models, Molecular; Molecular Conformation; Piperidines; Receptors, Opioid, mu; Recombinant Proteins; Structure-Activity Relationship | 2003 |
Elucidation of the bioactive conformation of the N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of mu-opioid receptor antagonists.
Topics: Animals; CHO Cells; Cricetinae; Cricetulus; Crystallography, X-Ray; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Ligands; Models, Molecular; Molecular Conformation; Piperidines; Radioligand Assay; Receptors, Opioid, mu; Stereoisomerism; Structure-Activity Relationship | 2006 |
Synthesis and pharmacological evaluation of novel octahydro-1H-pyrido[1,2-a]pyrazine as mu-opioid receptor antagonists.
Topics: Animals; CHO Cells; Cricetinae; Cricetulus; Crystallography, X-Ray; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Ligands; Molecular Structure; Pyrazines; Pyridines; Radioligand Assay; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Structure-Activity Relationship | 2006 |